| Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder (NCT07226661) | Supernus Pharmaceuticals, Inc. | 2026-01-19 |
| SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures (NCT07141329) | Supernus Pharmaceuticals, Inc. | 2025-07-30 |
| Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: (NCT07219927) | Supernus Pharmaceuticals, Inc. | 2025-03-31 |
| RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures (NCT06798896) | Supernus Pharmaceuticals, Inc. | 2024-12-30 |
| Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms (NCT06185985) | Supernus Pharmaceuticals, Inc. | 2024-03-25 |
| Evaluation of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk in Healthy Lactating Women (NCT06259331) | Supernus Pharmaceuticals, Inc. | 2023-05-23 |
| An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus (NCT05645432) | Supernus Pharmaceuticals, Inc. | 2023-05-10 |
| Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy (NCT05518578) | Supernus Pharmaceuticals, Inc. | 2023-02-07 |
| A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease (NCT05655520) | Supernus Pharmaceuticals, Inc. | 2022-12-14 |
| A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD) (NCT05619692) | Supernus Pharmaceuticals, Inc. | 2022-11-29 |
| A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment (NCT05318937) | Supernus Pharmaceuticals, Inc. | 2022-06-06 |
| 28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease (NCT05358821) | Supernus Pharmaceuticals, Inc. | 2022-05-26 |
| A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) (NCT05107128) | Supernus Pharmaceuticals, Inc. | 2022-01-26 |
| Mass Balance Study of NV-5138 in Healthy Male Subjects (NCT05384977) | Supernus Pharmaceuticals, Inc. | 2021-11-11 |
| Evaluating the Safety and Relative Bioavailability of Three SPN-817 Treatments (A, B and C) in Healthy Adult Subjects (NCT05102552) | Supernus Pharmaceuticals, Inc. | 2021-10-19 |
| A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting (NCT05059600) | Supernus Pharmaceuticals, Inc. | 2021-10-08 |
| Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants (NCT05049343) | Supernus Pharmaceuticals, Inc. | 2021-09-21 |
| Open-Label Study of SPN-812 Administered With Psychostimulants in Children and Adolescents With ADHD (NCT04786990) | Supernus Pharmaceuticals, Inc. | 2021-07-27 |
| Therapy for Migraine Prevention in Children 6-11 Years of Age (NCT04050293) | Supernus Pharmaceuticals, Inc. | 2020-07-14 |
| Open-label Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD (NCT04143217) | Supernus Pharmaceuticals, Inc. | 2020-01-23 |
| Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD (NCT04016779) | Supernus Pharmaceuticals, Inc. | 2019-11-20 |
| Classroom Study of SPN-812 in Children With ADHD (NCT04016792) | Supernus Pharmaceuticals, Inc. | 2019-08-01 |
| Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHD (NCT03638466) | Supernus Pharmaceuticals, Inc. | 2019-05-30 |
| A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B (NCT03787758) | Supernus Pharmaceuticals, Inc. | 2019-02-28 |
| A Study to Assess Electrophysiology, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of SAGE-718 Using Ketamine Challenge in Healthy Subjects (NCT03844906) | Supernus Pharmaceuticals, Inc. | 2018-12-27 |
| A Study to Assess the Electrophysiology, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response Using Magnetic Resonance Imaging of SAGE-718 Using a Ketamine Challenge in Healthy Subjects (NCT03770780) | Supernus Pharmaceuticals, Inc. | 2018-11-12 |
| A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects (NCT03771586) | Supernus Pharmaceuticals, Inc. | 2018-09-24 |
| A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD) (NCT03665038) | Supernus Pharmaceuticals, Inc. | 2018-09-07 |
| Functional MRI Study in Healthy Children Engaged in Aggressive Behaviors (NCT03615703) | Supernus Pharmaceuticals, Inc. | 2018-08-10 |
| Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment (NCT03597503) | Supernus Pharmaceuticals, Inc. | 2018-07-31 |
| BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures (NCT03474770) | Supernus Pharmaceuticals, Inc. | 2018-04-10 |
| Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide) (NCT03944785) | Supernus Pharmaceuticals, Inc. | 2017-11-30 |
| Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD (NCT03247556) | Supernus Pharmaceuticals, Inc. | 2017-11-20 |
| Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD (NCT03247517) | Supernus Pharmaceuticals, Inc. | 2017-11-02 |
| Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD (NCT03247543) | Supernus Pharmaceuticals, Inc. | 2017-10-31 |
| Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD (NCT03247530) | Supernus Pharmaceuticals, Inc. | 2017-10-20 |